Abstract
Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level of suspicion and prompt initiation of adequate antifungal treatment are mandatory. Epidemiology, risk factors, diagnostic algorithms, and different approaches in antifungal therapy for invasive aspergillosis in non-neutropenic patients are reviewed.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 458-458 |
Numero di pagine | 1 |
Rivista | Critical Care |
Volume | 18 |
Numero di pubblicazione | 4 |
DOI | |
Stato di pubblicazione | Pubblicato - 2014 |
All Science Journal Classification (ASJC) codes
- Terapia Intensiva e Rianimazione
Keywords
- Adrenal Cortex Hormones
- Antifungal Agents
- Aspergillosis
- Chronic Obstructive
- Communicable Diseases
- Critical Illness
- Emerging
- Humans
- Immunocompromised Host
- Incidence
- Intensive Care Units
- Opportunistic Infections
- Prevalence
- Prognosis
- Pulmonary Disease
- Risk Factors